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Ratio of Metastatic Lymph Nodes to Total Number of
Nodes Resected is Prognostic for Survival in Esophageal
Carcinoma
Clive J. Kelty, MB, ChB, PhD, FRCSEd, FRCS(Gen Surg),* Catherine W. Kennedy, RMRA,†
and Gregory L. Falk, MBBS, FRACS, FACS*†
Introduction: The role of the number of metastatic nodes in
esophageal cancer surgery is of interest. We assess predictors of
survival after oesophagectomy for esophageal and gastroesophageal
junction malignancy.
Methods: Prospective data of consecutive patients undergoing
oesophagectomy and systematic lymphadenectomy between 1991
and 2007.
Results: Of 224 patients, 148 patients (66%) had adenocarcinoma,
70 (31%) squamous cell carcinoma, and 6 (2.6%) were other tumor
types. Five-year survival was 43% with hospital mortality of 3.5%.
Locoregional recurrence occurred in 14%. The total number of
affected nodes significantly reduced survival (four or more meta-
static nodes). Further analysis of the ratio of nodes affected to the
total number resected showed a significant decrease in survival as
the percentage of positive nodes increased (p  0.001).
Conclusions: Patients undergoing surgery for esophageal cancer
should be staged according to a minimum total number of metastatic
lymph nodes and ratios because this more accurately predicts sur-
vival than current staging systems.
Key Words: Esophageal cancer, Esophagectomy, Lymphadenec-
tomy, Staging.
(J Thorac Oncol. 2010;5: 1467–1471)
Adenocarcinoma of the esophagus is increasing in inci-dence more rapidly than any other cancer in the Western
world.1 The mainstay of treatment for this and squamous cell
carcinoma remains surgical, namely esophagectomy, despite
advances in other therapies. However, the overall prognosis
for these patients is dismal, with survival in most countries
around 10%. Outcomes after surgery are marginally better
with reported 5-year survival rates averaging 25%.2–4 It is
known that these tumors spread radially via the lymphatic
system, thus resection of the primary tumor and lymphade-
nectomy are advocated.5 The rationale for lymphadenectomy
is primarily based on the Japanese experience in gastric
cancer. However, the evidence for this in esophageal carci-
noma is less clear and remains a controversial issue.6 Intu-
itively, the more radical the resection, the more lymph nodes
(LNs) will be removed, and this will improve staging of the
disease and possibly affect prognosis, either by reducing or
delaying locoregional recurrence, or increasing the disease
free survival. However, the extent of lymphadenectomy is not
standardized among surgeons, and there is a lack of random-
ized trials assessing this issue.
The number of LNs removed during lymphadenectomy
is of value, in particular the presence of LN metastases,
because it seems that there is prognostic significance in the
number of metastases This may have treatment implications.
According to the Sixth International Union Against Cancer
tumor node metastasis (TNM) classification (which is also
uniform with the sixth edition of the American Joint Com-
mittee on Cancer staging), any regional LNs with metastatic
involvement were staged as “N1.”7,8 However, this binary
grading was controversial because there is increasing evi-
dence to suggest that the number of metastatic nodes, rather
than positive or negative metastatic nodes, may affect prog-
nosis. It has been shown in several studies that increasing
numbers of resected nodes with metastatic deposits is one of
the most important prognostic factors; there is a significant
reduction in survival after curative oesophagectomy for both
squamous cell carcinoma and adenocarcinoma.9–20 This was
addressed by the seventh edition of the American Joint
Committee on Cancer Staging Manual that was published in
January 2010.21 The new classification now recognizes dif-
ferent nodal classification (N1-3) based on coarse groupings
of the number of nodes involved (0, 1–2, 3–6, and 7,
respectively).
It has also been suggested that it is not simply the
number of nodes that is important but that the LN yield needs
to be adequate for staging17–19; the numbers suggested range
from 10 to more than 18. This is in stark contrast to the sixth
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TNM classification that only required six nodes.7 This was
not specifically addressed in the seventh edition; however, it
states that an adequate lymphadenectomy requires between
12 and 22 nodes and advocates as extensive a lymphadenec-
tomy as possible.
What remains less clear, however, is whether it is
simply the absolute number of metastatic nodes that is im-
portant or whether the ratio of affected nodes to nodes
resected may be an independent prognostic factor.
We currently perform a systematic two-field lymphad-
enectomy that has been reported previously.22 Therefore, we
examined survival in a contemporary cohort of patients di-
agnosed with esophageal carcinoma who underwent an en-
bloc lymphadenectomy, and whether the extent of LN me-
tastases, in particular the ratio of nodes affected compared
with the total yield of resected nodes, had a prognostic effect
on survival.
METHODS
A prospective database of patients who had carcinoma
of the esophagus and gastroesophageal junction (excluding
proximal lesions and Siewert type III adenocarcinomas) and
who underwent subtotal oesophagectomy and systematic
lymphadenectomy in a tertiary referral center between 1991
and 2007 was collected. Routine preoperative evaluation
included upper gastrointestinal endoscopy with biopsy, com-
puterized tomography scan, and selective endoscopic ultra-
sound. Staging laparoscopy was also performed on a selective
basis for junctional (Siewert II) tumors. Operative fitness was
determined by clinical assessment, pulmonary function test-
ing, arterial blood gas, and cardiac imaging, as clinically
indicated. All patients fit for surgery and assessed as feasible
for R0 resection despite evidence of nodal disease on imaging
were offered surgical resection on an all-comers policy.
Latterly in the series, patients were offered neoadjuvant
therapy if the tumor was considered borderline resectable
(borderline attachment to pleura, pericardium or aorta or
bulky tumors and adjacent lymphadenopathy) on preopera-
tive staging. This constituted three cycles of ECX (epirubicin,
cisplatin, and capecitabine) in adenocarcinomas and two
cycles of cisplatin and 5-fluouracil in squamous tumors. The
surgical procedure comprised Ivor-Lewis oesophagogastrec-
tomy and systematic two-field en-bloc lymphadenectomy. All
patients had given prior consent for data to be collected on the
database. We assessed demography, in-hospital mortality, the
extent of resection, the number of nodes resected, those
affected by metastatic deposits and survival. The follow-up
protocol consisted of 3-monthly consultant review for 2
years, followed by 6-monthly review thereafter to 5 years and
then annually. When it was not possible for face-to-face
review, information was obtained from the patient’s primary
physician. Further imaging was based on clinical grounds.
Data were analyzed with the method of Kaplan-
Meier,23 log-rank test, and Cox’s proportional hazards regres-
sion for survival analysis.24
RESULTS
Two hundred twenty-four consecutive patients were
identified from the database.
There were 162 men (72%) with a median age of 65
years (range, 29–84 years). One hundred forty-eight patients
(66%) had adenocarcinoma, 70 (31%) squamous cell carcinoma,
and 6 (3%) were other tumor types (2 neuroendocrine tumors).
Neoadjuvant therapy was given to 67 patients (30%). Of these,
13 with extensive squamous carcinoma were given concurrent
45 Gy radiotherapy. The median length of follow-up was 20
months (range, 1–174). One hundred eighty-four patients (82%)
had been reviewed within the last 12 months (up to August
2008). The in-hospital mortality was 3.5%. A R0 resection was
achieved in 88%, R1 (defined as tumor extending to the resec-
tion margin, including circumferential margin) in 10%, and R2
in 2%. The AJCC stage distribution was as follows: stage 0, n
11 (5%); stage 1, n 38 (17%); stage 2A, n 46 (20%); stage
2B, n  37 (16%); stage 3, n  78 (35%); and stage 4, n  14
(6%). Nodal disease was detected in 122 patients (54.4%).
Overall 5-year survival as plotted by Kaplan-Meier analysis was
43%, with a median survival of 33.6 months (Figure 1). Patients
with node-positive disease had a 5-year survival of 23% (me-
dian, 31 months). Locoregional recurrence occurred in 14% after
a median of 11.5 months. There was also a significant relation-
ship in survival between both the TNM stage of disease (p 
0.001; Figure 1) and increasing depth of tumor invasion (p 
0.001). However, there was no relationship between either
histologic type of tumor (adenocarcinoma versus squamous cell;
p  0.66; Figure 2) and tumor site (mid, lower esophagus, and
gastroesophageal junction; p  0.96). There was no significant
difference between patients who had undergone neoadjuvant
therapy or surgery alone (p 0.98; Figure 3). With multivariate
analysis, independent predictors for diminished survival were
male sex, age older than 75 years, and residual tumor.
The median number of nodes resected in the specimens
was 17 (range, 12–26). Analysis of the number of nodes
affected by metastatic disease showed that there was a sig-
nificant relationship between those having four or more nodes
involved. Patients with less than four nodes involved had a
median survival of 17.7 months, but four or more nodes
FIGURE 1. Patient survival according to AJCC (6th Edition)
TNM staging.
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involved gave a median survival of 9 months (p  0.001;
Figure 4). Further analysis of the ratio of nodes affected to the
total number resected showed a significant decrease in sur-
vival as the percentage of positive nodes increased (p 
0.001; Figure 5). In patients who had less than 20% of nodes
involved, median survival was 27.4 months, falling to 22
months for 20 to 40% of nodes affected, 12.8 months for 40
to 60% of nodes involved, and when more than 60% of
resected nodes were affected, survival was a dismal 6.5
months.
DISCUSSION
It is well recognized that there is an adverse effect on
survival when there are metastatic nodes after esophageal
resection. However, the extent of LN resection remains con-
troversial because some series have reported similar out-
comes after minimal resection compared with those advocat-
ing dissections that are more extensive.4 However, it remains
a justifiable principle of cancer surgery, as demonstrated in
other tumors, that more radical resections with LN clearance
can confer a survival benefit.25 It is based on this principle
that en-bloc resection of the esophagus is more likely to
achieve a real R0 resection by not leaving positive LNs, and
so results are likely to be better after surgery. The level of
local recurrence will also be improved (as in this series).
Extensive resection with lymphadenectomy has shown im-
proved survival in reported series with 5-year survival rates
of 40 to 50%,4,22 compared with a contemporary meta-
analysis of 25%.2
The sixth TNM staging system only took account of
whether regional LN metastases are present or not, and this
was translated into a stage grouping. This created a problem,
because there was no provision for the absolute number of
nodes affected, which has been shown in several series to
predict survival more accurately.9–20 It also failed to measure
the completeness of the lymphadenectomy. The general con-
sensus of these studies is that four or more metastatic nodes
is prognostic, and this is borne out in our series, because there
FIGURE 2. Overall survival in patients according to histo-
logic subtype.
FIGURE 3. Survival according to the administration of neo-
adjuvant therapy versus surgery alone.
FIGURE 4. Survival according to absolute number of lymph
node metastases resected.
FIGURE 5. Overall survival in patients stratified with in-
creasing metastatic lymph node ratios.
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was a significant reduction in survival after surgery in pa-
tients who had four or more nodes affected. Based on this, the
seventh revision of the TNM system to include subgroups of
the N stage hopes to allow more accurate prediction of
survival.
The sixth revision of the TNM classification states that
a minimum number of six nodes should be sampled to allow
classification of the nodal status.7 This is low, particularly
when it takes into account other sites, such as colon and
stomach, which require 12 and 15 nodes, respectively. It
should also be noted that these cancers also have different
node groupings (N1-3). The seventh edition is less specific
in the absolute number of nodes resected; however, it
states that the degree of lymphadenectomy required is
dependant on the T stage. In reality, this is unrealistic,
because the staging is based purely on pathologic stage. It
is difficult to justify the extent of surgery performed purely
on clinical staging, because more extensive lymphadenec-
tomy has been shown to provide a survival benefit,22 and
clinical staging is less accurate and so difficult to establish the
“right” number and extent of nodal removal. It is simply
necessary to be able to adequately remove LNs without
excess morbidity and mortality.
A recent study by Bogoevski et al.18 has examined
whether the number of nodes resected should be higher. They
suggested that a minimum number of 18 should be examined
to allow accurate staging. In 255 patients who underwent
oesophagectomy with curative intent, the numbers of nodes
resected were stratified into three groups, less than 6, 6 to 18,
and 19 and higher. This approach demonstrated that patients
with either N0 or N1 disease with less than 19 nodes had
similar survival rates. They concluded that it is probable that
this could be explained by a degree of missed metastatic
disease when fewer LNs are analyzed, as with low numbers
there is a risk of sampling error (i.e., not finding metastatic
nodes and grouping a patient as N0 when in fact the patient
should be grouped as N1).
Bogoevski’s group further reviewed the ratio of LNs
with metastatic involvement. Groups were identified with
ratios of less than 11%, 11 to 33%, and more than 33%. This
demonstrated significantly improved survival in patients with
lower ratios and was further borne out by the observation that
there was little difference in patients staged as N0 with 18 or
fewer nodes analyzed (median survival 36 months) and in
patients with N1 disease but more than 18 nodes resected and
a low ratio of affected nodes (median survival 28 months).
They concluded that the current nodal staging classification
was insufficient, and that LN ratios should be considered in
substaging within the pN1 classification. In our series, the
median LN yield was 17. Further analysis of node yield
during two separate time periods, namely the first (1991–
1998) and second (1999–2006) half of the series showed
average yields of 13 and 20 nodes, respectively. However,
this was not associated with any difference in survival be-
tween the two groups. There was no change of technique
during the series, so this finding implies that the increased
detection of nodes was due to improved pathologic reporting
rather than being due to more radical surgery or experience of
the surgeons.
Other series have examined the prognostic effect of
involved node to total node ratios,9,12,13,17,18–20 but they have
only examined an arbitrary-defined cutoff point (between 0.1
and 0.3). Two recent studies have tried to stratify this further
by using two cutoff points to stratify patients to three risk
groups and have shown that there are further prognostic
differences.18,20 We have tried to be less arbitrary and to
substratify the ratios more fully in our series. This has shown
significant differences between four different groups with
cutoff points of 0.2, 0.2 to 0.4, 0.4 to 0.6, and more than 0.6.
We would suggest that this is a more sensitive analysis,
particularly when there are significant differences between
these groups. However, it is important to recognize that a
systematic lymphadenectomy will remove more nodes and
allow more accurate staging using this system because when
the total number of nodes removed increases, it will likely
drive down the ratios to a better prognostic group.
At the time of analyzing the data and constructing this
article, the seventh edition was not in print, and hence this
discussion was based on the previous classification (as is all
the current evidence). The new classification now recognizes
different nodal classification (N1–3) based on coarse group-
ings of the number of nodes involved. Although there is now
recognition that increasing nodal involvement (and so tumor
burden) is prognostic, there is still no requirement for assess-
ment of the ratio of nodal metastases to total lymphadenec-
tomy. Indeed, the manual states that the data do not support
LN ratio; paradoxically, this article and others however do
support this.9–20 The main issue with LN ratio is that the
denominator (i.e., the number of nodes sampled) is variable
and that this can dilute the prognostic value. In this study, the
number of nodes resected was higher (range, 12–26) than
previously required, and the recommendation from the AJCC
is that ideally 12 to 22 nodes should be sampled.
Previous editions of the TNM classification ignored
histologic type, but the seventh edition specifically separates
adenocarcinoma and squamous cell carcinoma and stages
them differently. The data indicate that squamous cell carci-
noma has a poorer prognosis, but this was not borne out in
this series (and paradoxically this trend was reversed, albeit
not significantly).
One of the weaknesses of the new staging classification
is that it is based purely on pathologic data of patients who
have undergone surgery alone. It is increasingly common for
patients to receive neoadjuvant therapy because data show
that this is of benefit in patients with operable esophageal
cancer.26 Because many studies report varying definitions of
responses, the specific reason for this benefit is less clear; it
may be due to downstaging of the primary tumor or from
treatment of tumor cells that have already spread. Despite this
reported benefit, our analysis did not show a significant
difference between these groups.
Both the findings of no difference in overall survival
based on the histologic type, or use of neoadjuvant therapy,
adds further weight to the argument that it is the degree of
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lymphadenectomy performed rather than the tumor site per se
that is important.
We note that this cohort of patients were a heteroge-
neous group, with different tumor types resected. However,
the same conclusions can be drawn, because the pattern of
LN metastases for the tumor sites is similar. LN involvement
is a significant prognostic indicator of overall survival and
disease-free survival, and as the number of involved nodes
increases, it may suggest a greater tumor burden or more
aggressive tumor biology, and so the likelihood of locore-
gional or systemic recurrence could be assumed to be higher.
However, this series shows that prognosis after surgery can
be significantly affected by the ratio of affected nodes to the
number of nodes resected after radical resection, and there-
fore stage grouping of the LN is not simply positive or
negative. In an age when it is increasingly important to stage
patients correctly to make decisions on adjuvant therapy,
inclusion into clinical trials, and inform patients, this type of
prognostic information is vital to both physicians and patients
alike. This study demonstrates that the accuracy of the current
TNM classification is suboptimal and that there should be
revision of the nodal reporting, taking into account the ratio
of involved nodes to the total number resected. Therefore, we
propose oesophagectomy with radical en-bloc lymphadenec-
tomy should become the standard of care, because it is
apparent that survival is likely to be improved after surgery.
It also provides optimal staging and is therefore a better
prognostic indicator of survival than current conventional
pathologic reporting.
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